Condition: Breast Cancer · Sponsor: Eli Lilly and Company
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
This description comes directly from the study's public registry record.
There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or · 13176154559 · ClinicalTrials.gov@lilly.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic of Scottsdale | Scottsdale, Arizona, United States | Not Yet Recruiting |
| UCLA Medical Center | Los Angeles, California, United States | Completed |
| UCSF Medical Center at Mission Bay | San Francisco, California, United States | Recruiting |
| Stanford University Hospital | Stanford, California, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Not Yet Recruiting |
| Winship Cancer Center Emory University | Atlanta, Georgia, United States | Completed |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Completed |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Washington University Medical School | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Completed |
| Wilmot Cancer Institute | Rochester, New York, United States | Not Yet Recruiting |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05307705